Announcement • Nov 10
HyEnergy S.A. to Report Q3, 2025 Results on Nov 12, 2025 HyEnergy S.A. announced that they will report Q3, 2025 results on Nov 12, 2025 Announcement • Aug 20
HyEnergy S.A. to Report Q2, 2025 Results on Aug 30, 2025 HyEnergy S.A. announced that they will report Q2, 2025 results at 11:30 AM, Central European Standard Time on Aug 30, 2025 Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to zł2.44, the stock trades at a trailing P/E ratio of 39.8x. Average trailing P/E is 37x in the Life Sciences industry in Europe. Total loss to shareholders of 79% over the past three years. Announcement • May 15
HyEnergy S.A., Annual General Meeting, Jun 10, 2025 HyEnergy S.A., Annual General Meeting, Jun 10, 2025. New Risk • Oct 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 489% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (489% increase in shares outstanding). Revenue is less than US$1m (zł373k revenue, or US$93k). Minor Risk Market cap is less than US$100m (zł127.6m market cap, or US$31.7m). Announcement • Sep 07
Inno-Gene S.A. announced that it expects to receive PLN 14.25 million in funding Inno-Gene S.A announced a private placement to issue 28,500,000 Series H shares at an issue price of PLN 0.5 per share for the gross proceeds of PLN 14,250,000 on September 5, 2024. Reported Earnings • Aug 11
Second quarter 2024 earnings released Second quarter 2024 results: Net loss: zł424.0k (loss narrowed 5.8% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • Jul 16
Inno-Gene S.A., Annual General Meeting, Aug 13, 2024 Inno-Gene S.A., Annual General Meeting, Aug 13, 2024, at 12:00 Central European Standard Time. Location: ul sciegiennego 20, poznan Poland Announcement • May 30
Inno-Gene S.A. to Report Q4, 2023 Results on Jun 30, 2024 Inno-Gene S.A. announced that they will report Q4, 2023 results on Jun 30, 2024 Reported Earnings • May 20
First quarter 2024 earnings released First quarter 2024 results: Net loss: zł218.3k (loss narrowed 30% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 16
Full year 2023 earnings released: zł0.26 loss per share (vs zł0.35 loss in FY 2022) Full year 2023 results: zł0.26 loss per share (improved from zł0.35 loss in FY 2022). Revenue: zł1.13m (up 276% from FY 2022). Net loss: zł1.46m (loss narrowed 26% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 29 percentage points per year, which is a significant difference in performance. Announcement • Jan 13
Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding Inno-Gene S.A announced a private placement to issue 500,000 Series G shares at an issue price of PLN 2 per share for the gross proceeds of PLN 1,000,000 on January 11, 2024. New Risk • Nov 15
New major risk - Revenue and earnings growth Earnings have declined by 7.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł18.1m market cap, or US$4.49m). Announcement • Sep 06
Inno-Gene S.A., Annual General Meeting, Sep 27, 2023 Inno-Gene S.A., Annual General Meeting, Sep 27, 2023, at 12:00 Central European Standard Time. Announcement • Jul 28
Inno-Gene S.A. to Report Fiscal Year 2022 Results on Aug 31, 2023 Inno-Gene S.A. announced that they will report fiscal year 2022 results on Aug 31, 2023 Announcement • Jun 30
Inno-Gene S.A. to Report Fiscal Year 2022 Results on Jul 31, 2023 Inno-Gene S.A. announced that they will report fiscal year 2022 results on Jul 31, 2023 Reported Earnings • May 21
First quarter 2023 earnings released First quarter 2023 results: Revenue: zł737.0k (down 93% from 1Q 2022). Net loss: zł312.0k (down 109% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 10
Full year 2022 earnings released: EPS: zł0.058 (vs zł1.08 in FY 2021) Full year 2022 results: EPS: zł0.058 (down from zł1.08 in FY 2021). Revenue: zł16.3m (down 46% from FY 2021). Net income: zł330.0k (down 95% from FY 2021). Profit margin: 2.0% (down from 21% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorated over the past week After last week's 16% share price decline to zł7.12, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 224% over the past three years. Reported Earnings • Aug 19
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł4.22m (down 65% from 2Q 2021). Net loss: zł893.0k (down 119% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment deteriorated over the past week After last week's 19% share price decline to zł9.40, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 39x in the Life Sciences industry in Europe. Total returns to shareholders of 411% over the past three years. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 23% share price gain to zł10.30, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 37x in the Life Sciences industry in Europe. Total returns to shareholders of 448% over the past three years. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 27% share price gain to zł8.81, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 412% over the past three years. Announcement • Jun 08
Inno-Gene S.A., Annual General Meeting, Jun 30, 2022 Inno-Gene S.A., Annual General Meeting, Jun 30, 2022, at 12:00 Central European Standard Time. Announcement • Jun 03
Inno-Gene S.A. (WSE:IGN) acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million. Inno-Gene S.A. (WSE:IGN) acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million on May 31, 2022. Inno-Gene S.A. also acquired 150 shares for a total nominal value of PLN 0.075 million. Post transaction, Inno-Gene S.A. holds 19.36% stake in Naturativ
Inno-Gene S.A. (WSE:IGN) completed the acquisition of additional 10.72% minority stake in Naturativ on May 31, 2022. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improved over the past week After last week's 23% share price gain to zł6.12, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 48x in the Life Sciences industry in Europe. Total returns to shareholders of 222% over the past three years. Reported Earnings • May 20
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: zł10.1m (up zł8.63m from 1Q 2021). Net income: zł3.53m (up 208% from 1Q 2021). Profit margin: 35% (down from 76% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.0%. Valuation Update With 7 Day Price Move • May 09
Investor sentiment deteriorated over the past week After last week's 23% share price decline to zł5.00, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 163% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorated over the past week After last week's 21% share price decline to zł7.46, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 49x in the Life Sciences industry in Europe. Total returns to shareholders of 293% over the past three years. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 27% share price gain to zł9.48, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 40x in the Life Sciences industry in Europe. Total returns to shareholders of 458% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 26% share price decline to zł7.00, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 645% over the past three years. Reported Earnings • Feb 16
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: zł1.35 (up from zł0.28 in FY 2020). Revenue: zł29.9m (up zł25.2m from FY 2020). Net income: zł7.69m (up 389% from FY 2020). Profit margin: 26% (down from 34% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) also surpassed analyst estimates. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has increased by 119% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 24
Investor sentiment deteriorated over the past week After last week's 24% share price decline to zł10.60, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 41x in the Life Sciences industry in Europe. Total returns to shareholders of 846% over the past three years. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 17% share price gain to zł10.50, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 48x in the Life Sciences industry in Europe. Total returns to shareholders of 727% over the past three years. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment deteriorated over the past week After last week's 16% share price decline to zł9.79, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 51x in the Life Sciences industry in Europe. Total returns to shareholders of 183% over the past three years. Reported Earnings • Aug 21
Second quarter 2021 earnings released The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: zł11.0m (up zł9.80m from 2Q 2020). Net income: zł5.97m (up zł5.28m from 2Q 2020). Profit margin: 54% (down from 59% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 49% per year. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 21% share price decline to zł8.22, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 59x in the Life Sciences industry in Europe. Total returns to shareholders of 233% over the past three years. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improved over the past week After last week's 15% share price gain to zł10.80, the stock trades at a trailing P/E ratio of 21.3x. Average trailing P/E is 61x in the Life Sciences industry in Europe. Total returns to shareholders of 218% over the past three years. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improved over the past week After last week's 18% share price gain to zł11.00, the stock trades at a trailing P/E ratio of 21.7x. Average trailing P/E is 59x in the Life Sciences industry in Europe. Total returns to shareholders of 310% over the past three years. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment deteriorated over the past week After last week's 21% share price decline to zł10.62, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 59x in the Life Sciences industry in Europe. Total returns to shareholders of 299% over the past three years. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improved over the past week After last week's 27% share price gain to zł14.31, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 57x in the Life Sciences industry in Europe. Total returns to shareholders of 477% over the past three years. Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorated over the past week After last week's 34% share price decline to zł14.00, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 57x in the Life Sciences industry in Europe. Total returns to shareholders of 438% over the past three years. Reported Earnings • May 21
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł1.50m (up zł1.28m from 1Q 2020). Net income: zł1.15m (up zł1.19m from 1Q 2020). Profit margin: 76% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 77% per year, which means it is well ahead of earnings. Reported Earnings • Feb 17
Full year 2020 earnings released: EPS zł0.84 (vs zł0.029 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: zł7.05m (up 419% from FY 2019). Net income: zł4.80m (up zł4.96m from FY 2019). Profit margin: 68% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 87% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 10
New 90-day low: zł19.70 The company is down 69% from its price of zł64.00 on 12 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 3.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: zł21.00 The company is down 53% from its price of zł45.00 on 29 September 2020. The Polish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 8.0% over the same period. Recent Insider Transactions • Oct 04
President of the Management Board recently sold zł3.2m worth of stock On the 29th of September, Jacek Wojciechowicz sold around 100k shares on-market at roughly zł32.46 per share. This was the largest sale by an insider in the last 3 months. This was Jacek's only on-market trade for the last 12 months. Is New 90 Day High Low • Sep 28
New 90-day high: zł30.00 The company is up 127% from its price of zł13.20 on 30 June 2020. The Polish market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 21% over the same period. Announcement • Aug 21
Inno-Gene S.A. (WSE:IGN) acquired unknown stake in INNGEN SA for PLN 0.01 million. Inno-Gene S.A. (WSE:IGN) acquired unknown stake in INNGEN SA for PLN 0.01 million on August 20, 2020. Inno-Gene acquired 0.03 million shares. Jacek Wojciechowicz, acting as the President of Management Board of Inno-Gene, was appointed a member of the Supervisory Board of Inngen SA.
Inno-Gene S.A. (WSE:IGN) completed the acquisition of unknown stake in INNGEN SA on August 20, 2020.